海欣股份(600851.SH)：维生素B6注射液通过仿制药一致性评价

Core Viewpoint - The company, Haixin Co., Ltd. (600851.SH), announced that its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplement application of the chemical drug "Vitamin B6 Injection," which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The approved drug, Vitamin B6 Injection, is primarily indicated for the prevention and treatment of Vitamin B6 deficiency and for treating isoniazid poisoning [1] - Additional indications include use during pregnancy, radiation sickness, and vomiting caused by anticancer drugs, as well as seborrheic dermatitis [1] - The drug is also indicated for total parenteral nutrition and for nutritional deficiencies due to inadequate intake, as well as for progressive weight loss [1] Group 2 - Increased demand for Vitamin B6 may arise in conditions such as pregnancy and lactation, hyperthyroidism, burns, chronic infections, fever, congenital metabolic disorders, congestive heart failure, long-term dialysis, and malabsorption syndromes associated with liver and biliary diseases [1] - The drug is also indicated for gastrointestinal diseases, including celiac disease, tropical enteritis, localized enteritis, and persistent diarrhea, as well as post-gastrectomy [1] - It is specifically indicated for newborns with hereditary Vitamin B6 dependency syndrome [1]